1. Home
  2. PPCB vs DRMA Comparison

PPCB vs DRMA Comparison

Compare PPCB & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PPCB

Propanc Biopharma Inc.

N/A

Current Price

$0.12

Market Cap

3.2M

Sector

N/A

ML Signal

N/A

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.45

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PPCB
DRMA
Founded
2007
2014
Country
Australia
United States
Employees
N/A
8
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PPCB
DRMA
Price
$0.12
$1.45
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
1.2M
1.8M
Earning Date
02-17-2026
03-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.59
52 Week High
$10.69
$7.33

Technical Indicators

Market Signals
Indicator
PPCB
DRMA
Relative Strength Index (RSI) 28.08 52.25
Support Level N/A $0.63
Resistance Level $0.40 $2.29
Average True Range (ATR) 0.02 0.11
MACD 0.00 0.05
Stochastic Oscillator 7.02 45.21

Price Performance

Historical Comparison
PPCB
DRMA

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology for patients suffering with acne. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin.

Share on Social Networks: